About Biotech Insider Alert

Biotech Insider Alert is a powerful new service for investors. It tracks the most crucial milestones in a new drug or medical technology’s journey to the marketplace – and shows you how to invest for maximum gains. A longtime bioscience investing expert, editor Ernie Tremblay has a proven ability to identify only the companies that have likely breakthrough winners in the fast-moving bioscience sector. He pinpoints the exact calendar date the pharmaceutical company behind a new therapy can skyrocket in value. These stocks often pop by double and triple digits overnight, then run up to even bigger gains in the months ahead. It’s happened thousands of times. And now you can be one of the “insiders” grabbing those bioscience profits for yourself. Click here to see the latest news in biotech stock.

If you’re an Biotech Insider Alert subscriber, click here to login. If not, see below for more information about Biotech Insider Alert.

Hi. I’m Ernie Tremblay with an urgent alert…

If you’re retired – or even if you were born before 1961 – you need to pay very close attention.

Your life may be in imminent danger, and the next few minutes could save you or a loved one…

Time is short, so let me give you the facts…

At this moment, a new, highly infectious strain of “Old Man’s Friend” is quietly sweeping the heartland, killing nearly every 10 minutes

This emerging crisis has caught the U.S. government, as well as the big pharmaceutical companies, completely OFF GUARD and UNPREPARED…

And it’s easy to see why…

You see, this infection is one of history’s most prolific killers…

In fact, for centuries, it was a virtual DEATH SENTENCE.

Once it had you in its grip, you were on borrowed time…

But that changed in 1928 with the discovery of antibiotics…

In fact, thanks to the infection-fighting miracle of antibiotics, this killer’s death rate plummeted over 90%…

Problem solved! 

A whole new era of modern medicine was underway. And for the last 88 years, antibiotics have kept this killer at bay…

Happy days, for sure.

And as a result, the FDA, the CDC, and the big pharmaceutical companies dropped their guard…

What’s worse, they STOPPED searching for new ways to battle this deadly infection…

Take a look…

There hasn’t been a new class of antibiotics developed since 1984! 

That’s a 30-year void!

In short, the healthcare industry made a huge bet that existing antibiotics would work forever…

Big mistake… deadly mistake…

You see, through a terrifying mutational phenomenon – MIT calls it horizontal gene transfer – this deadly strain has become ANTIBIOTIC-RESISTANT

Let me repeat…

This highly infectious, deadly strain has become antibiotic-resistant…

Suddenly, it’s as if antibiotics had never been invented.

We’ve been thrown back to the 19th century…

Arjun Srinivasan, M.D., an expert on infectious outbreaks at the CDC, confirms the facts, saying:

We’re in the post-antibiotic era.”

And Tom Frieden, the Director of the CDC, takes it a step further, saying:

“It’s the end of the road for antibiotics.”

As Margaret Chan, Director of the United Nations World Health Organization puts it:

“Doctors will have to face their patients and say, ‘Sorry, there’s nothing we can do for you.’

That means that once this highly infectious killer slips into your system, there’s often NOTHING doctors can do…

According to the CDC, 4.5 million unsuspecting Americans become infected by this killer per year…

And retirees are dropping like flies…

Look: This killer is already the eighth leading cause of death in the United States. It’s killing more people than prostate cancer and breast cancer!

And now that it’s BREACHED the antibiotic firewall, the death toll is mounting…

Just last month, and every 30 days, this deadly mutation kills an average of 3,690 retirees…

That’s one death almost every 10 minutes…

And while everyone is at risk, retirees are nearly six times more likely to fall victim.

Make no mistake: It’s a grisly death…

The ironic thing is, we used to call this infection the “Old Man’s Friend.”

That’s because it could bring a quick, relatively painless end to suffering…  

In other words, if a 95-year-old patient was confined to the hospital, and facing drawn-out suffering, this infection could deliver a quick, peaceful end.

As you may have guessed, I’m talking about pneumonia…

But please understand: This new strain is very different from your grandfather’s pneumonia…

And let me be clear: There’s nothing “peaceful” of “friendly” about it…

The new pneumonia strain is SAVAGE…

HIGHLY INFECTIOUS…

And it kills without mercy.

Thing is, it can start so innocently…

You could wake up one morning with a slight cough…

Or maybe just a headache…

Maybe you’re feeling some fatigue… lack of energy.

Maybe you get a bit breathless at the top of the stairs.

Nothing all that unusual, right?

Wrong. And it can escalate fast…

Once infected, there’s often nothing doctors can do…

Just ask Christina Michaels, whose 68-year-old father, Paul, was infected at his weekly church bingo game.

It started slow. No cause for alarm…

But things quickly took a terrifying turn for the worst…

Paul was admitted to the hospital and given the most powerful antibiotics known to man…

Nothing worked…

And as Paul struggled for breath, the doctors looked on helplessly…

To this day, Christina is haunted by his moans… his screams… and his cries for help as the infection cut-off his oxygen from the inside…

As I said, it’s a grisly death, anything but peaceful…

In the end, all the doctors can do is administer an IV of morphine so your final hours are less agonizing…

Sounds like a nightmare, I know.

Every 10 minutes, another American gets the bad news.

Perfectly healthy men…

Women…

In big cities…

In small towns…

In the suburbs…

And even the countryside…

Nowhere is safe as this highly infectious strain of pneumonia spreads at an alarming rate.

The scary part is, this infection is not limited to the bedridden…

It’s gone public and can strike anytime, anywhere…

All it takes is one microscopic cell…

And because these pathogens have grown so strong – and so incredibly resilient – they can survive on sterilized surfaces… without a human host.

One could be hiding on a doorknob at your neighbor’s house, left behind by a visiting grandchild…

Or on the banister or escalator handrail at the mall…

On the elevator button…

It could come from an errant sneeze in the movie theatre or library…

A cough at the grocery store or on the bus…

Heck, it could be hiding on your salad bowl at the Olive Garden.

It doesn’t matter how you get it.

Not one bit…

Once you’re infected, the chances of survival are grim…

In fact, across the United States, antibiotics only stop pneumonia about 50% of the time…

That means if you get this new strain of pneumonia, go ahead and flip a coin.

Heads you live…

Tails, you die…

You’ve got a better chance of surviving a HEART ATTACK!

And, depending where you live, it can be even more deadly.

For instance, if you live in Texas, your risk goes up… Same in Georgia… And Florida…

And it’s getting worse every day…

In fact, we are fast approaching the day where pneumonia is UNSTOPPABLE…

Sounds like a doomsday scenario, I know. But let’s look at the facts…

In 1996, drug resistance in the United States was only 10%…

Not bad. Still dangerous. But chances were good you’d survive…

However, in the last 20 years, a terrifying mutational phenomenon – known as horizontal gene transfer – has elevated drug resistance by a staggering 400%…

And now leading antibiotics only work about HALF the time. Again, it’s like flipping a coin. Heads you live, tails…

Thing is, through horizontal gene transfer, pneumonia is continuing to mutate and grow stronger, and stronger, and stronger…

At the current rate, antibiotics will be completely useless by 2021.

That’s only five years away, and it’s happening right before our eyes.

In some parts of the world, Azithromycin, once hailed as a miracle drug, fails 96% of the time!

In other words, you can forget the coin flip!

You get infected by this highly contagious killer and you’re a goner…

We are looking at the Middle Ages all over again!  

Imagine lying in a hospital bed, struggling to breathe…

You hold your spouse’s hand as a doctor walks in, armed with a clipboard and stethoscope.

As he approaches the bed, you look up hopefully. 

Everything’s going to be ok, you think. He’ll give you a dose of antibiotics. You’ll be home in time for Jeopardy!

But he doesn’t have good news.

“I’m sorry,” your doctor says. “The drugs no longer work. There’s nothing we can do…”

NOTHING WE CAN DO…

A final verdict with no chance of appeal.

And here’s the part that makes me absolutely furious.

Flat-out enraged…

The big pharmaceutical companies have completely ignored this emerging crisis…

In fact, they’ve acted like it doesn’t exist!

That’s right…  

It’s as if the drug industry – giant companies like Pfizer, Johnson & Johnson, and Merck – made a conscious decision NOT to fight this killer pneumonia strain.

Maybe they thought they had it beat…

Or maybe they decided to focus on a different market…

After all, 85% of pneumonia victims are over 65. Maybe the drug companies decided to spend their efforts on patients with a longer “shelf-life.”

It doesn’t really matter. Because the bottom line is the same:

Big Pharma hasn’t developed a new antibiotic since 1984…

That’s over 30 years without a new drug to stop pneumonia!

Stefano Bertuzzi, CEO of the American Society for Microbiology says:

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines."

During that same 30 years, deadly pathogens have been MUTATING, becoming stronger everyday…

And now a hyper-virulent strain of pneumonia is RESISTANT to the most powerful antibiotics known to man.

Bottom line: We’ve reached the day of reckoning. 

Dr. Margaret Chan, Director of the United Nation’s World Health Organization warns:

“We’re running out of time. Doctors facing patients will have to say, ‘Sorry, there is nothing I can do for you.’

The old drugs no longer work…

As CDC Director Tom Frieden said:

“The medicine cabinet is empty. It’s the end of the road for antibiotics.”

And because Big Pharma hasn’t developed a class of new drugs since 1984, once you become infected, there’s often NOTHING doctors can do for you…

Fortunately, there is a solution…

And it comes from a most surprising source…

A tiny North Carolina company has spent the last 10 years – an entire decade – developing a whole new class of drug

A new drug that can do what old-line antibiotics can’t…

A new drug that’s poised to usher in the next chapter in modern medicine, saving millions of lives in the process…

A new drug with an unprecedented level of sophistication.

As you’re about to see, it’s like something out of "Star Wars"…

Truly amazing stuff…

It’s a bit ironic, actually…

You see, instead of focusing on quick profits like Big Pharma has done the last 30 years, this tiny company put all their energy into saving lives…

And now, they’re about to be rewarded mega-fold.

In fact, because this company is tiny, you could turn a $1 stake into a potential $10, $15, even $25.

Imagine putting down $10,000 today and waking up in a few months’ time to $250,000…

Extraordinary?

Yes. And as you know, nothing in the market is guaranteed. But let me show you why this could be just the beginning of an epic run…

This new drug is the first and only of its kind…

A breakthrough on par with the discovery of penicillin or the polio vaccine.

In fact, the FDA has determined this drug is so critical to modern society, they’ve issued a special classification – called a QIDP – rushing it to market.

And the way this drug works is like something out of “Star Wars”…

Let me show you why…

As you may know, leading antibiotics like Azithromycin stop pneumonia by attacking its ability to produce protein.

Of course, protein is essential to life. 

So when you shut down a cell’s ability to produce protein, not only do you kill it, but you also stop its ability to spread.

Now, Azithromycin attacks the pneumonia cell’s “ribosome.” And because the ribosome is the cell’s “protein factory,” the cell dies…

But here’s the thing: Antibiotics attack only one site on the pneumonia cell’s ribosome.

Over time, the cell mutates and figures out how to survive this single-pronged attack.

In addition, cells use a molecular phenomenon known as horizontal gene transfer to share intelligence with other cells.

That’s right. The killer cells are teaching other cells how to be more lethal…

In a study conducted by MIT, researchers determined that different strains can quickly swap genes with each other through a global network.

And it’s not just pneumonia. It’s every strain of bacteria on the planet – over 10,000 different species – all sharing intelligence with each other…

This is terrifying stuff…

Just like people exchange information via Twitter, texts, and email, bacteria shares information.

Once a bacteria cell figures out how to survive, it can share the information with other cells and even other species of bacteria.

It literally TRANSFERS its survival intelligence, thereby creating an ARMY of drug-resistant – and deadly – pathogens…  

That’s exactly what’s happened over the last 30 years…

While old antibiotics have remained stagnant… pneumonia cells have EVOLVED, MUTATED, and BECOME UNSTOPPABLE…

Suddenly, a hyper-virulent strain of pneumonia is IMMUNE to Azithromycin.

It’s killed over 1,000 Americans in the last week alone.

One death every 10 minutes. And doctors are desperate, praying for help… 

That’s why this new drug is critical… a true breakthrough of epic proportions…

You see, while old Azithromycin attacks the ribosome in one location, the new drug attacks the strains of bacteria's ribosome in THREE DISTINCT LOCATIONS

This is hugely important for two main reasons…

First, because the drug is brand new, bacteria are not immune to it. 

Consequently, in extensive placebo-controlled, double-blind clinical studies, this new drug proved up to 16 times more effective than Azithromycin.

Think of an old Civil War rifle taking pot shots at its enemy…

Now imagine a battalion of high-powered laser guns conducting a synchronized and lethal attack from three sides!

That’s the difference between Azithromycin and the new drug…

Point is, while Azithromycin is failing, unable to stop this highly infectious strain of pneumonia, this new drug is up to 16 times more potent.

In other words, it eviscerates pneumonia!

And because of the sophisticated three-prong attack, the pneumonia cells are unable to mutate…

Imagine a snowball fight…

In a one-on-one fight, the pneumonia cells can effectively analyze and decode the attack strategy.

This allows it to mutate and adapt, ultimately becoming drug-resistant…

But with the new drug, it’s a whole different ball game.

Suddenly, the pneumonia is being attacked from three different sides.

While antibiotics and pneumonia are playing old-fashioned checkers, the new drug is playing computerized chess! 

And while pneumonia is able to defend itself from one or two angles, it can’t stop an assault from three sides at the same time.

In other words, if all three of the pneumonia’s “protein factories” are shut down, it simply can’t survive.

More importantly, it can’t mutate…

This is groundbreaking.

With antibiotics failing, and a hyper-virulent strain of deadly pneumonia killing every 10 minutes, this couldn’t come at a better time.

In fact, this new drug may well be the greatest medical achievement since penicillin.

A breakthrough that could save millions of lives…

And as you can imagine, the profit potential is off the charts…

You see, right now, this company books a mere $27 million in annual sales.

That's one-tenth of one percent the sales of pharmaceutical giant Johnson & Johnson. 

It’s tiny!

But it won't stay small for long…

Remember, this strain of pneumonia has killed over 1,450 Americans in the last 10 days alone.

That’s one death every 10 minutes, and the CDC projects the annual death toll will hit 53,000 by December…

With antibiotics failing, doctors are desperate for a new drug that saves lives…

This throws open the door to the $2 billion pneumonia drug market… a market now ripe for the taking…

How big a slice of that $2 billion will this new drug grab?

Well, in theory, they could take over the entire market…

After all, antibiotics are failing. As a result, people are dying…

And the FDA has issued a special classification that grants this new drug a five-year monopoly!

That’s right. I said monopoly…

Think of it…

If this $27 million company uses its FDA-designated monopoly to seize the entire market, they’d be looking at revenues of $2 billion…

That’s a staggering 7,300% sales surge…

If the stock followed suit, it’d turn a $1 stake into $73…

That’s good enough to turn $10,000 into $730,000 in a single trade…

Now, let me be clear. I’m very conservative. I like to “over-deliver” on my promises.

So let’s remember, the FDA could surprise us. Approval is never guaranteed.

And I’m going to tell you right up front: This new drug is not going to grab the entire pneumonia drug market even if it gets approved. At least not right away.

But it’s almost certainly going to get a big piece of the pie…

Here’s a stunning fact: Extensive market research determines that doctors are clamoring for this new drug. 

They want it. And they want it now. In fact, 93% of doctors surveyed said they are likely to use this new drug instead of traditional antibiotics.

Pharmacies are on board as well. Because pneumonia is life-threatening, patients can’t afford to wait a day or two.

As a result, about 85% of pharmacies will stock the new drug within days of its launch.

One pharmacists says:

“Patients can’t wait 24 hours for this new drug to be ordered. So we will stock it on the first day available.”

Talk about instant market penetration! 

And this goes along with the company’s FDA-mandated monopoly…

With that in mind, what would happen if this company captured 90% of the $2 billion market?

We’d be looking at revenues of $1.8 billion, a sales surge of 6,600%…

If the stock follows, that’d be good enough to turn $10,000 into $660,000.

Given that 93% of doctors are begging for this new drug and the FDA is handing the company a five-year monopoly, this projection could be absolutely attainable…

And it’s happened before. In fact, Amgen’s anemia drug, Epogen, held a monopoly for 23 years, racking up $40 billion.

Still, I’d prefer we get even more conservative…

So let’s see what happens if this new life-saving breakthrough only captures HALF the market…

I think that’s very realistic. After all, old antibiotics are failing, and with lives on the line, doctors are not going to take any chances.

Think about it. 

If you had a patient struggling to breathe, his lungs filling with fluid, his internal organs being devoured by a hyper-virulent strain of pneumonia… what would you do?

Would you use an old antibiotic that no longer works?

Or would you use a new drug that’s proven to be 16 times more powerful?

It’s a no-brainer! 

Upon FDA approval, this drug will hold a MONOPLY.

In addition, 93% of doctors say they are likely to use it. 

To say this drug could secure HALF the market is an understatement of epic proportions. But again, let’s keep it conservative…

At half the market, this tiny $27 million company would see revenues of over $1 billion…

That’s a sales surge of over 3,600%…

A stock following this course could jump from $1 to $36…

Good enough to turn $10,000 into $360,000…

That’s nearly half-a-million profit potential in one trade! 

A massive, massive win. 

No matter how you slice it, this tiny $27 million company is poised for an epic run. And there’s something else that I need to tell you about this company…

Something unique…

Something powerful…

Something that makes their phenomenal upside potential a virtual foregone conclusion.

You see, while well-known diseases – like diabetes, asthma, and arthritis – have scores of drug companies working on cures…

Some lesser-known diseases, even horrific killers like drug-resistant pneumonia, often go unaddressed.

So in an effort to make sure these devastating diseases are treated, the U.S. Government has assigned this new drug a special designation…

In fact, the FDA has designated it a Qualified Infectious Disease Product (QIDP) for Fast-Track review.

Not only does this designation put it on the bullet train to FDA approval – it also gives the drug an additional five-year period of market exclusivity in the U.S., if approved.

In other words, it gives this new drug a MONOPOLY…

Now, let me be clear: The U.S. Government doesn't just throw “fast-track” classifications around.

It’s incredibly hard to get…

And as you can imagine, the benefits of receiving fast-track are two-fold…

First, killers like drug-resistant pneumonia get treated. People who would otherwise have no hope are saved. 

Second, early investors – savvy folks who understand the power behind the government's fast-track status – have the chance to get flat-out rich.

For example, Alexion Pharmaceuticals developed a drug called Soliris® to treat blood disorders.

Because of the horrendous nature of blood disorders, plus the fact that – like drug-resistant bacteria – there were no real options, Soliris® got fast-track status…

And look at what happened:

The first arrow shows where the drug received Fast-Track Status.

The second arrow shows how high the stock reached.

It jumped from $3.44 to $195.

That's a phenomenal 5,668% return…

Good enough to turn $10,000 into $576,000.

Again, when Americans are at risk, the U.S. government will pave the way for small companies that can deliver a solution.

The great part is, investing in these life-changing treatments means you are doing good – perhaps even saving yourself – all while getting rich.

Take what happened with Questcor Pharmaceuticals…

Questcor received fast-track status for Acthar®, a drug designed to treat "infantile spasms," a devastating disease affecting babies.

Questcor's stock jumped from 40 cents in 2007… to over $95 in 2014.

That's a 211-fold increase – a 21,000% gain.

Good enough to turn $10,000 into $2.1 million in less than seven years.

Here's another example, this time with Jazz Pharmaceuticals…

The company received fast-track status for JZP-8, a drug designed to control seizures in Epilepsy patients.

The result?

Not long after it received Fast-Track Status, the stock price was 55 cents. Just five years later, it soared to $170

See where that first arrow is pointing? 

That's where Jazz received fast-track status. The second arrow shows the heights it reached – a stunning 300-fold gain, more than 30,000%.

Good enough to turn $10,000 into over $3 million in less than five years.

Over and over, fast-track status has proven to be a launching pad for tiny companies with breakthrough drugs…

Celldex's drug Rindopepimut – designed to treat brain cancer – received Fast-Track Status… and the stock jumped from $2.05 to $37.98. That's a 1,852% gain. 

Keryx Biopharmaceuticals received Fast-Track Status for their drug Perifosine – designed to treat multiple myeloma.

The stock jumped from $1.30 to $16.50. That's a 1,269% gain.

And how about Amgen… 

It was a struggling little start-up until their drug Epogen® – designed to treat anemia – qualified for Fast-Track Status.

Before the Government even made it official, Amgen's stock started to move… ultimately soaring from 9 cents to over $144 per share…

That's a phenomenal 160,000% return.

Good enough to turn $10,000 into $16 million.

Heck, it's so good you could have become a millionaire even if you had only started with $700!

Now, of course, no one can predict the market. And even an FDA approval doesn’t guarantee gains like these.

But when you look at the facts, I think you’ll agree: This tiny company has similar potential…

Thanks to the U.S. government, it's on the bullet train to FDA approval.

It's already sailed through two FDA clinical trials. And final FDA approval is imminent…

In fact, the FDA is so eager to get this new drug deep into market, they are issuing a rare “double-shot decision,” expected in December…

When that happens, I believe this tiny stock could soar…

Remember, right now, this company's sales are a mere $27 million.

But this new drug could rocket revenue all the way to $1 billion. And that's if they only tap HALF the market… in the U.S. alone!

That's a sales surge of over 3,600%…

Good enough to turn every $1 stake into $36 in a single trade…

And like I said before, that’s only the beginning. 

You see, this new drug does more than fight pneumonia.

In extensive clinical studies conducted over the last decade, it’s proven to stop nearly every strain of deadly bacteria on the planet…

And the moment it passes FDA approval, the U.S. Government is likely to call on it to help solve an even wider and deadlier crisis…

This is critical – life-saving!

You see, it’s not just pneumonia that’s become drug-resistant…

It’s every form of deadly bacteria on the planet…

That’s right… we are now facing an army of deadly bacteria that far exceeds the threat of pneumonia alone.

Remember, through horizontal gene transfer, different species of bacteria can share their deadly traits with each other…

The situation is so severe that the U.S. Department of Defense has sounded the alarm, saying:

"This heralds the emergence of a truly pan-drug resistant bacteria."

And while pneumonia kills every 10 minutes, drug-resistant bacteria kills every 45 seconds!

That’s 700,000 lives a year… a death every 45 seconds!

With antibiotics failing, experts project that the death toll could soar to 10 million people a year.

That’s one victim every three seconds!

The World Health Organization (WHO) explains the danger at hand, saying:

“Immediate action is needed to stop the world from heading towards pre-antibiotic era in which all achievements made in prevention of communicable diseases will be reversed. Common infections and minor injuries may once again kill millions.”

In the United States, health officials are already distressed over drug-resistant infections, including gonorrhea.

Dr. Jonathan Mermin, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, explains it this way:

“Our last line of is weakening. If resistance continues to increase and spread, current treatment will ultimately fail and 800,000 Americans a year will be at risk for untreatable gonorrhea.”

Bottom line: We are facing an escalating threat from an army of savage infections, including gonorrhea, pneumonia, MRSA, and even deadly Legionnaire’s disease.

And while old-line antibiotics like Azithromycin can’t stop this crisis…

The new drug I’ve been telling you about could…

That’s right. This new drug could kill a vast army of bacteria that are rapidly becoming drug resistant. 

Pneumonia. MRSA. Gonorrhea. Legionnaire’s disease. It could kill them all.

Now, I’ve already explained that the pneumonia drug market is $2 billion. 

Pretty big, right? But it’s nothing compared to the entire $45 billion antibiotic market…

Remember, 93% of doctors – as well as 85% of pharmacies – are clamoring for this new drug, saying they will use it over current antibiotics.

The upside potential is staggering. If this drug replaced 90% of the $45 billion antibiotic market, it’d be a sales surge of 150,000%…

And even if it only captured half the market, we’d be talking about a sales surge of 80,000%…

If the stock follows suit, it’d be good enough to turn $10,000 into $8 million in a single trade.

Is that possible? 

Well, it’s ONLY HALF of what Amgen generated, so yes, it’s not only possible, it’s happened before!

And I'm not the only one who believes this stock is ready to make history.

Insiders are loading up!

That’s right…

In advance of the imminent FDA decision – expected by December 27 – folks inside this company are betting their own money at a frenetic pace.

The company's President and CEO, Executive Vice President, even their Board Members…

These are people with extensive industry experience… over 165 years!

They were trained at the most esteemed medical institutions in the world, including Harvard Medical School, Johns Hopkins, Stanford University, and Duke Medical School

And the company’s top players have personally walked 19 drugs through the FDA approval process… and have been responsible for marketing 27 different antibiotics!

Do you think for one second these guys don't know what's about to happen?

Look, these are veterans of the drug development business. They can spot a winner a mile away. And make no mistake: They spot one now…

Remember, this company has received a special classification from the FDA, granting it a five-year monopoly!

In fact, the FDA is so desperate to get this drug to market, they are issuing a rare DOUBLE-SHOT FINAL DECISION.

On December 27, they are announcing their decision for oral uses of this new drug. 

And on December 28, they are announcing their decision for intravenous uses.

That’s right. The FDA is in such a rush to get this new drug to market that not only has it granted fast-track status… but it’s also completing final review of both forms of the new drug at an accelerated pace.

A rare DOUBLE-SHOT FDA FINAL-DECISION!

It’s expected by year-end…

And experience tells me critical news that could rocket the share price into orbit could come a whole lot sooner.

You see, this tiny $27 million company’s CEO has been summoned to a face-to-face advisory meeting with the FDA outside Washington, D.C. on November 4.

I’m confident the CEO could emerge with a smile on his face that will ignite an insider buying frenzy…

As you can imagine, savviest biotech investors on the planet are piling into this tiny company. 

For example, Palo Alto Investors – an elite team of world-class investors with degrees from Harvard, Duke, and Stanford – has taken a $45 million position…

Dr. Sam Stewart, a former Columbia University professor turned billion-dollar money manager has also taken a $40 million position…

Combined with insiders, they've already locked up nearly 90% of the available shares.

And to tighten things further, we’ve just gotten word that a legendary billionaire has taken a position in this tiny $27 million company…

His name is Dr. James Simon, and he’s regarded as one of the most astute investors of all time…

He’s a former Harvard mathematics professor and NSA Code-Breaker.

He was elected to the National Academy of Sciences (NAS) and helped develop the ground-breaking “String Theory” of quantum physics…

But his scientific achievements take a back seat to his investment prowess…

He’s has amassed a personal fortune of $15.5 billion, and his $65 billion hedge fund has a history of picking monster homeruns.

Questcor…

Jazz Pharmaceuticals

And Amgen…

And now he’s suddenly increased his position in this tiny $27 million company by a whopping 571%…

Obviously, Dr. Simon is more than a little optimistic about the imminent FDA DOUBLE-SHOT DECISION, due December 27…

In fact, in the coming days, I wouldn’t be surprised to see him swallow the remaining shares in one swift swoop…

That means you need to move fast to secure a ground-floor position BEFORE you completely miss out.

Could this company soar 21,000% like Questcor?

Or 30,000%, like Jazz Pharmaceuticals?

Or 160,000%, like Amgen?

Listen, I can't promise those kinds of returns. No one can. These were rare and exceptional cases that made early investors flat-out rich.

But I can tell you this: When you look at the facts…

When you consider that the CDC says:

The medicine cabinet is empty for some patients. It’s the end of the road for antibiotics…”

When you consider the U.S. government granted this tiny company the Fast-Track advantage they gave Questcor, Jazz Pharmaceuticals, and Amgen…

When you look at the desperate demand for this new drug: Over 90% of doctors are clamoring for it…

When you consider that even if they only capture half the desperate pneumonia market alone, it’d be a sales surge of over 3,600%…

When you consider that if they capture even HALF the antibiotic market, it’d be a sales surge of over 80,000%…

When you look at the urgency with which the U.S. government is rushing this to market…

When you look at the FDA preparing to issue a rare DOUBLE-SHOT FINAL DECISION

You can only come to one conclusion…

We are on the verge of a historic run that could make early investors very rich.

Now, let me show you how to get in on the ground floor and turn every $1 stake into $15… $25… even $50 or more…

The Reason I'm in This Business

I've spent the last 25 years closely following the most exciting developments in medical science, including new breakthrough drugs

And after three decades, I've mastered a powerful three-phase formula that can accurately determine whether a new drug will be a breakthrough winner – or a casualty of an FDA denial.

My experience, insight, and rigorous due diligence typically translate into big wins for folks who follow my recommendations.

For example, I recently uncovered a company called Aegerion Pharmaceuticals, based in Cambridge, Massachusetts.

Aegerion had developed a drug to treat HoFH. If you're not familiar with it, HoFH is a horrible disease that not only causes premature death, but also terribly disfigures people afflicted with it – especially kids.

For me, this was a no-brainer…

I recommended readers get in on Aegerion Pharmaceuticals (AEGR) at roughly $17 per share.

Over the next year, Aegerion rocketed from about $17 per share… up to and past my recommended close price of $77… all the way to $101 per share.

That's a potential 494% gain in 12 months…

Not bad.

I isolated Sangamo BioSciences, too, based in Richmond, California.

Sangamo had developed a treatment that had the potential to become a major breakthrough in the treatment of HIV… and to save millions of lives.

Another no-brainer…

I recommended Sangamo BioSciences (SGMO) at $7.92 per share.

Over the next few months, Sangamo bolted up to – and past – my recommended close price of $10.49… climbing as high as $24.12.

That's a potential gain of 304% in less than nine months.

I could go on and on.

In fact, on December 19, 2014, I spotted Esperion Therapeutics.

Esperion had developed a drug to treat high cholesterol.

Now, typically, people with high cholesterol take statin drugs.

The problem is, in the U.S. alone, as many as seven million adults have stopped statin therapy because the side effects are too much to bear.

Esperion's new drug offered a solution…

Again, a no-brainer!

I recommended Esperion Therapeutics at about $35 a share.

Less than three months later, Esperion had surged to $75.55 a share.

I instructed readers to sell half their position for a 104% win.

That's a double! And it gets even better…

Just three days later, Esperion nearly doubled again! I instructed readers to sell half their remaining position at $114 for a 211% win.

Now these are small companies. Stocks like these, including our next potential winner, can often be volatile with added risk. The last thing you want to do is blindly chase a stock like that with no plan.

So you’ll want to follow my instructions carefully and pay special attention to my “buy up to” price so you don’t over pay.

Stocks like these, including our next potential winner, can often move up and down quickly.

If you do that, you’ll have the chance to join the rest of my readers who, as you can imagine, are thrilled with the gains they're seeing.

People like Robert Samson, who wrote to congratulate me:

"Glad to write and congratulate you on your picks! Very decisive win and truly impressive recommendation. Annualized, that is a 2,978% rate of return."

Andrew Rogers is another one of my readers who’s thankful for the help with his retirement:

"I am up $10K in a little over one month. Soon we will have a very nice retirement after suffering huge losses at the hands of Fidelity."

Terrence Yardley shared how he’s made tens of thousands of dollars:

"I made close to 30k profit… Thank you VERY much – You are the best advisor!"

Gary Smith sent me this kind message:

"Thanks so much. 1,484% on an annualized basis. I am very pleased with the recommendations you have provided and look forward to more."

And Dr. Harold Parker summed it all up:

"Your service is the best value I've come across in the 30 years I've been investing and trading. A hearty Thank You!"

As you can see, people who follow my research have a chance to make money hand over fist.

That doesn't happen by luck.

In order to produce these kinds of results, I've developed a three-phase formula that can spot winners with stunning accuracy.

Let me show you how it works:

Phase 1:
The Science Must Work

I see this all the time…

A biotech company announces they've developed a new drug to cure cancer.

Exciting news, but beware.

Just because a company develops a new drug… doesn't mean it's going to work.

Investing in a company before the science is proven is a COSTLY MISTAKE.

That's why when I isolate a new product, I put it through an extensive evaluation process that leaves no stone unturned.

I DEMAND rock-solid evidence the drug works BEFORE I even consider giving it a recommendation.

I dive into available pre-clinical and clinical data… evaluate statistical significance indicators… and take a rigorous look at how the new drug or device functions, potential side effects, and risk factors.

Listen: Over the years, I've been one-on-one with some of the world's most accomplished scientists.

These are medical experts – M.D.s and Ph.D.s – with roughly 235 years of combined experience… people who have devoted their lives to interpreting scientific data…

They work at esteemed institutions, places like Harvard Medical School… Yale University… UCLA School of Medicine… and Stanford University, just to name a few…

They've given me a special understanding – an insider's perspective – on the FDA approval process.

If the news is good… if the product is safe and effective…

If the product has the ability to relieve suffering and save lives…

Then it’s a go!

After careful evaluation of this breakthrough new drug, I can unequivocally say, this is the most exciting breakthrough since the discovery of penicillin.

And the way it works is like something out of “Star Wars”…                                   

Remember, leading antibiotics like Azithromycin can only attack from one direction.

But this new drug attacks with laser-power from three different directions.

The pneumonia has no chance! 

Now, once I’m convinced a new drug works, I move it to Phase 2 of my evaluation process.

Phase 2:
The Market Must Be Hungry

I love it when a new drug works.

Thing is, even if a drug works, that doesn't mean it will be an investment success.

In order for a new medical discovery to meet my criteria for investment, it must serve a market that is ready, willing, and able to embrace it.

In other words, the product has to be able to sell. And sell big time…

That's why I evaluate the potential market for each and every drug I recommend. In this study, I need a POSITIVE answer to five critical questions:

  • Does this new drug help people?
  • Do surgeons and doctors WANT and NEED this new drug?
  • Will insurance companies embrace and back it?
  • Will it dominate its market?
  • And will new revenues have a significant impact on the company's stock price?

A "no" to any of these questions, and the new product is off the table as far as investment goes.

Yes, it feels good to get behind a product that helps people. But why not get behind a product that both helps people AND has the potential to make you rich?

The tiny $27 million company I'm recommending today does both.

Doctors love it. They are literally clamoring for it! In fact, market research show that 93% of medical doctors are likely to prescribe this drug over antibiotics like Azithromycin for this deadly strain of pneumonia!

That’s over 90% market acceptance! 

This is the kind of potential that comes along very rarely… and when it does, fortunes are made.

Even if this company captures HALF of a very desperate pneumonia drug market, we’re looking at a sales surge of over 3,600%… and the stock could follow suit.

Now, once I determine that the product is positioned to deliver explosive potential upside to investors, I move it to Phase 3 of my evaluation process.

Phase 3:
Timing Is Everything

This is where a lot of investors get into trouble.

They hear an exciting story about a new drug or device and jump right in.

Here's the thing: If the product is still in the early stages of development, it could be years before the stock moves.

Plus, in the early stages, it's impossible to know if it actually works.

At the same time, if you wait too long, you'll miss out on the big money. 

The key is to get in AFTER the science has yielded positive results… but BEFORE the general public rushes in, sending the stock into orbit.

Where is the perfect point of entry?

In this case, you need to get in immediately BEFORE final FDA approval.

And the reason is simple: If you wait until after the FDA approval, you could miss out on 90% of the wins.

Folks who get in early, BEFORE the FDA sends it soaring, can grab up shares for pennies on the dollar and magnify their winnings mega-fold…

The Facts Are Undeniable:
We Are Ready for Lift-Off

That's exactly where we are today with the tiny company I've been telling you about…

I've been immersed in biotech, medicine, and science for a quarter-century…

And I can tell you without reservation: The opportunity I'm tracking today offers phenomenal upside potential… maybe the biggest I've ever seen.

This new drug is the biggest medical breakthrough since penicillin. Not only is it world-changing. It is WORLD-SAVING…

The first new class of antibiotic in nearly 30 years!

And it comes at a critical time…

At this moment, a deadly strain of hyper-virulent pneumonia has broken through the antibiotic firewall.

The strongest antibiotics in the world have failed, and this killer strikes every 10 minutes…

The big pharmaceutical companies have been caught flat-footed. In fact, they haven’t developed a new type of antibiotic in nearly 30 years.

Fortunately, this tiny $27 million company could have the solution…

Not only could their patented new drug save millions from a grisly death, it could also make you very wealthy, very soon.

As I run this tiny company through my rigorous three-phase evaluation process, it keeps looking stronger and stronger.

First, the science behind it is brilliant… the drug’s three-phase attack is 16 times stronger than antibiotics, and shuts down pneumonia’s ability to become drug-resistant.

Second, doctors are desperate for this new drug. In fact, 9 out of 10 say they will prescribe it ahead of all other antibiotics

Think about that. If this tiny $27 million-in sales company captures even half of the pneumonia drug market, we’d be looking at a 3,600% sales surge.

And as they expand to fight other deadly strains of bacteria they could be looking at a sales surge of 80,000%.

That’s good enough to potentially turn a $1 stake into $80…

Third, the timing couldn't be better.

Not only has this company passed my evaluation process with flying colors…

I am recommending it with an "URGENT BUY" rating.

This company has already sailed through the first two stages of the approval process. 

And at this moment, the FDA is preparing its DOUBLE-SHOT FINAL DECISION, due December 27 and December 28, 2016.

Make no mistake: This is the same kind of opportunity that sent Amgen soaring 160,000%…

In advance of the FDA’s announcement, insiders have grabbed up nearly 90% of the available shares alongside institutions.

These guys know exactly what's about to happen, and time is of the essence.

In fact, this tiny $27 million company’s CEO has been summoned to a critical FDA meeting on November 4.

I’m telling you now: When the CEO emerges from this meeting with a knowing smile (as I expect he will), the stock could go vertical…  

Bottom line: You need to act today… right now!

Here's how to do it…

Go ahead and give my research advisory service, Biotech Insider Alert, a risk-free try today.

The moment you do, you'll get all the details on the tiny $27 million company I've been telling you about.

Most importantly, you'll get the name of the company, its stock symbol, and detailed instructions on how to buy it for a small fraction of its real value.

I’ll also give you detailed share price instructions so you don’t overpay.

And that's only the tip of the iceberg.

You see, I'm constantly evaluating up-and-coming drugs and medical technologies that could make early investors rich.

I’m talking about incredible breakthroughs that are in development right now, including:

Stop the Zika Virus in Its Tracks! The deadly Zika virus has already shut down parts of the United States, and is spreading fast. There’s currently no cure, but one company has a promising development that could help put an end to this mosquito-borne terror!

A 3D Printer for New Body Parts! This incredible breakthrough means a whole new level of life-saving potential. This 3D printer uses living human cells instead of ink! In the future, we could even see doctors printing new vital organs: New hearts. New lungs. New kidneys. Amazing!

Microscopic Robots That Travel in Your Blood Stream and Zap Cancer! Scientists have developed miniature robots that can patrol our bloodstreams and kill bacteria, pathogens, and even cancer! And unlike chemotherapy, they work without brutal side effects. This could be a total game-changer!

Incredible stuff… and that’s just the tip of the iceberg.

I’m currently tracking some incredible medical innovations, including:

  • A patented obesity pill that makes losing weight a breeze!
  • A pain-free blood test that takes the “OUCH” out of lab work!
  • A “Smart Teddy Bear” to comfort children in hospitals. Developed by MIT!

And we’re just getting warmed up. 

I’m confident you’ll find the medical sciences sector absolutely fascinating – and so darn lucrative!

With Biotech Insider Alert, you'll have everything you need to seize these breakthrough opportunities long before most investors even know they exist:

When I come across a breakthrough opportunity that passes my rigorous three-phase evaluation process, I'll issue an immediate "buy" alert via email, with all the details.

By the way, I’ll include the recommended buy price, as well as my forecast. Plus, when the time comes, I’ll let you know when to take profits.

Every Friday, you’ll also receive a weekly update so you'll always know exactly what’s happening with any stock I recommend.

In addition, you can sign up for Biotech Insider text alerts. Because these little drug stocks can move quickly, it's imperative you get in as close to my recommendation as possible. That's why, if you so choose, you can receive a message on your smartphone, alerting you to check your email for my latest recommendation.

Anytime you want to check the price of the stocks in the Biotech Insider Alert portfolio, simply log on and you'll see real time prices for all the picks. That way you always know where we stand with every single Biotech Insider recommendation.

And the instant you join you'll get your members-only password access to Biotech Insider Alert's exclusive site, where you'll find my most recent recommendations, all past alerts, every single update, and a link to the live portfolio track record.

Now, you may be wondering… how much does all this cost?

That's the best part, as I'll explain in a moment. But first, let me tell you about another company I'm recommending now…

Protecting the Global Blood Supply!
Urgent Buy High Flyer

Let me be clear right up front: This opportunity could prove volatile.

But for folks looking for an exciting – and potentially lucrative – run, look no further.

As you may know, a critical part of the FDA’s mission is to protect the U.S. blood supply.

In the past, contaminated blood has infected perfectly healthy people with AIDS, Hepatitis, and other deadly conditions.

And threats to the blood supply keep growing because of new killers like Zika and West Nile Virus…

Problem is, the existing screening system has extreme vulnerabilities. In fact, it’s like Swiss cheese: Full of holes…

Consequently, getting a blood transfusion today is a bit like playing Russian roulette. 

Fortunately, a tiny $6 company has a solution…

Not only does this company’s patented nucleic acid targeting mechanism screen for every imaginable contamination…

But it also locates and kills contaminations it discovers!

It even stops established threats, such as Hepatitis, HIV, and West Nile, as well as emerging pathogens such as Chikungunya, malaria, and dengue fever.

From an investment standpoint, it doesn’t get any better. You see, this system is the one and only of its kind…

This tiny $6 company is already approved in Europe, South America, and the Middle East.

And here’s the kicker…

The FDA has just issued urgent guidelines, telling ALL blood suppliers to hospitals, ERs, surgery centers, and trauma centers that it’s critical they use this tiny $6 company’s new blood screening system…

Talk about a monopoly!

With a 150 million transfusions a year, the global blood screening market is projected to be worth $2.5 billion by 2019.

Currently, this company has annual sales of just $34 million.

Even if their patented, one-and-only product captures HALF of the market, we’d be looking at a sales surge of nearly 3,600%.

And the stock could follow right along…

Folks who get in now could see a 978% return.

Maybe a whole lot more…

Insiders are in a frenzy, and it could be a wild ride. But the upside potential is absolutely staggering.

Of course, to maximize your returns, you need to get in early. So I encourage you to take action today…

All the details on this company, including its name and stock symbol, are yours the moment you agree to give my Biotech Insider Alert a risk-free try today…

This is just the beginning of the opportunities you'll hear about.

In fact, let me give you the details on one company I'm pulling the trigger on:

Breathing Life into 8 Million Americans! Strong Buy!

This next drug is a true miracle – a godsend! – that could impact you or a loved one in a profound way.

Let me ask you…

Do you ever experience shortness of breath while doing everyday activities?

Do you cough or wheeze frequently?

Do you ever feel tightness in your chest?

If you answered YES to any of these questions, please pay close attention.

You may be at risk for Chronic Obstructive Pulmonary Disease (COPD), a catch-all term for several lung conditions that make it hard to breathe.

Now, most folks have never heard of COPD…

It kills 120,000 Americans every year!

And there is currently NO CURE

Fortunately, a tiny medical firm has developed a true breakthrough in the treatment of COPD.

The patented drug could be best-in-class.

In fact, with a single daily dose, it magically clears air passages, and could breathe life into eight million Americans in need.

Currently, this tiny firm has a mere $9 million in sales. But the global market for COPD treatment is currently $11.3 billion.

Remember, there’s currently NO CURE, so the market is in desperate need.

That said, even if this patented breakthrough captures only 10% of the market –– we’re looking at a 12,200% sales surge.

That’s a 120-fold boost. And in the long run, the sky’s the limit.

Imagine turning every $1 invested into $10… every $10,000 into $100,000.

That’s the potential at hand, and I recommend you take a position ASAP.

The moment you sign up to give Biotech Insider Alert a try today, the details on this company, including its name and stock symbol, are yours.

As you can see, the potential to make a fortune in the biotech market is unmatched. Day after day, new drugs and devices are coming down the pipeline.

Not all of them make it through my evaluation process. But the ones that measure up offer a chance at staggering gains.

How much does all this cost?

Again, that's the best part…

As I've shown you, the biotech sector is legendary for minting new millionaires.

Where else could you start with $10,000 and turn it into $16 million in a single trade?

Where else could you turn 700 bucks into a $1.1 million windfall with a single stock?

Of course, not every new drug is a winner. But when you know what you're doing… and you can get in at the right time…

You're setting yourself up for life-changing potential – potential that resulted in:

  • 21,000% on Questor
  • 30,000% on Jazz Pharmaceuticals
  • 160,000% on Amgen

I could go on and on…

And remember, these are the kinds of opportunities you'll be hearing about every single week in Biotech Insider Alert.

Now, my research service has a very reasonable listed price.

But if you respond today – by clicking on the button below – you can lock in a full year for even less.

The moment you agree to give us a try, you'll get immediate access to the special report detailing the opportunities I told you about in this presentation.

You'll also have access to every single recommendation I've made – and will be making – in Biotech Insider Alert… including a handful of picks that are on the verge of major breakouts.

And you can get it all risk-free today…

In fact, just so you can be sure, here’s…

My Biotech Insider Alert
100% Money-Back "Triple Guarantee"

Guarantee Part I: If at any time during the first 90 days you're not completely delighted with the information, analysis, gains, or anything else about Biotech Insider Alert, simply let us know and we'll promptly refund every penny of your subscription price. No questions asked.

Guarantee Part II: Whether you invest in it or not, if this tiny $27 million new drug company doesn’t DOUBLE within 30 days of FDA approval, I’ll give you a second year of Biotech Insider Alert, absolutely free.

Guarantee Part III: If, after receiving a full year of service, our track record of Biotech Insider Alert recommendations doesn’t show at least five chances to double your money IN ADDITION TO the new drug stock I’m now recommending – that means at least five picks that have cleared optimum gains of 100% or more – simply let us know and we'll promptly refund every penny of your subscription price. Again, no questions asked.

I think you'll agree: That's as fair as it gets.

Go ahead and join us now. Just click on the button below and – at a minimum – take a look at my research on the tiny $27 million company before the week is out.

Even if you cancel your subscription, all of the information I give you – including all of my official "BUY" recommendations – are yours to keep.

That's right… you keep everything.

But you must act now…

The FDA’s DOUBLE-SHOT FINAL DECISION is expected on December 27 and December 28.

And based on my experience, the announcement could come sooner…

Any day now!

In fact, this tiny company’s CEO has been summoned to a critical meeting with the FDA on November 4

All eyes are watching, and when the CEO emerges from this meeting with a smile on his face, you can expect an epic buying frenzy…

Insiders have already grabbed nearly 90% of the available shares alongside institutions.

And we’ve just learned a legendary billionaire has taken a stake in this tiny $27 million company.

This man is a former Harvard mathematics professor turned hedge fund guru. 

He’s used positions in Questcor, Jazz Pharmaceuticals, and Amgen to amass a $15 billion personal fortune.

And now he’s boosted his position in this tiny $27 million company 571%…

If history is any indication, he could swoop in and take down the remaining shares any day now. Hesitate and you could miss out completely.

Remember, the entire $45 billion antibiotic market is up for grabs. And 93% of doctors are clamoring for this new drug. 

Even if this tiny company’s patented drug captures a mere half of the pneumonia drug market, we could see a 3,600% sales surge.

And as they expand to stop all strains of deadly drug-resistant bacteria, we could see a sales surge of 80,000%…

That’s good enough to turn every $1 stake into $80…

Imagine putting down $10,000, and waking up down the road with $8 million.

It’s happened before, and time is of the essence…

So please, don't miss out.

The opportunity is right in front of you. I urge you to seize it today. Simply click the button below.

Or, if you prefer speaking with someone over the phone, just call VIP Services Director Gabe Oropollo at 1.855.509.6600 (1.443.353.4770 for international callers) and mention Priority Code EERNS4RS.

He'll be happy to answer any questions you might have about the service.

 

Sincerely,

Micheal Robinson's signature

Ernie Tremblay
Founder, Biotech Insider Alert
October 2016

Join Now

Leave a Reply

Your email address will not be published. Required fields are marked *